Establishment of Risk Prediction Model for Retinopathy in Type 2 Diabetic Patients

Author(s):  
Jianzhuo Yan ◽  
Xiaoxue Du ◽  
Yongchuan Yu ◽  
Hongxia Xu
2021 ◽  
Author(s):  
Chengjun Zhu ◽  
Jiaxi Zhu ◽  
Lei Wang ◽  
Shizheng Xiong ◽  
Yijian Zou ◽  
...  

BACKGROUND Diabetes mellitus (DM) has become one of the most serious public health problems in the 21st century. chronic complications associated with type 2 DM (T2DM) increase the rate of disability, leading to untimely death and reduce the quality of life. In these complications, diabetic retinopathy (DR) is the most common one and could lead to secondary blindness. Despite retinal screening is first-of-choice for DR diagnosis, the limits of such screening equipments and experienced image readers restricted its applications, especially in those rural areas where DR risks even higher. Therefore, it’s essential to construct an easy-to-implement predictive model of the risk of DR in order to help predict individual morbidity and identify the risk factors of DR. OBJECTIVE Diabetic retinopathy (DR) has a high incidence rate in diabetic patients, the quality of life of whom will be seriously affected if not treated in time. This study aims to develop a risk prediction model for DR in type 2 diabetic patients. METHODS According to the retrieval strategy, inclusion and exclusion criteria, the relevant Meta analyses on DR risk factors were searched and evaluated. The pooled odds ratio (OR) or relative risk (RR) of each risk factor was obtained and calculated for β coefficients using logistic regression (LR) model. Besides, an electronic patient-reported outcome questionnaire was developed and 60 cases of DR and non-DR T2DM patients were investigated to validate the developed model. Receiver operating characteristic curve (ROC) was drawn to verify the prediction accuracy of the model. RESULTS After retrieving, eight Meta analysis with a total of 15654 cases and 12 risk factors associated with the onset of DR in T2DM, including weight loss surgery, myopia, lipid-lowing drugs, blood glucose control, course of T2DM, glycosylated hemo-globin, fasting blood glucose, hypertension, gender, insulin treatment, residence, and smoking were included for LR modeling. These factors, followed by the respective β coefficient was bariatric surgery(-0.942), myopia(-0.357), lipid-lowering drug follow-up <3y(-0.994), lipid-lowering drug follow-up >3y(-0.223), course of T2DM(0.174), glycated hemoglobin (0.372), fasting blood sugar(0.223), insulin therapy(0.688), rural residence(0.199), smoking(-0.083), hypertension(0.405), male(0.548), blood sugar control(-0.400) with constant term α = -0.949 in the constructed model. The area under receiver operating characteristic curve (AUC) of ROC curve of the model in the external validation was 0.912. An application was presented as an example of use. CONCLUSIONS In this study, the risk prediction model of DR was developed, which make individualized assessment for the susceptible DR population feasible and need to be further verified with large sample size application.


2021 ◽  
Vol 11 (8) ◽  
pp. 689
Author(s):  
Yu-Ting Hsiao ◽  
Feng-Chih Shen ◽  
Shao-Wen Weng ◽  
Pei-Wen Wang ◽  
Yung-Jen Chen ◽  
...  

Diabetic retinopathy (DR) is one of the most frequent causes of irreversible blindness, thus prevention and early detection of DR is crucial. The purpose of this study is to identify genetic determinants of DR in individuals with type 2 diabetic mellitus (T2DM). A total of 551 T2DM patients (254 with DR, 297 without DR) were included in this cross-sectional research. Thirteen T2DM-related single nucleotide polymorphisms (SNPs) were utilized for constructing genetic risk prediction model. With logistic regression analysis, genetic variations of the FTO (rs8050136) and PSMD6 (rs831571) polymorphisms were independently associated with a higher risk of DR. The area under the curve (AUC) calculated on known nongenetic risk variables was 0.704. Based on the five SNPs with the highest odds ratio (OR), the combined nongenetic and genetic prediction model improved the AUC to 0.722. The discriminative accuracy of our 5-SNP combined risk prediction model increased in patients who had more severe microalbuminuria (AUC = 0.731) or poor glycemic control (AUC = 0.746). In conclusion, we found a novel association for increased risk of DR at two T2DM-associated genetic loci, FTO (rs8050136) and PSMD6 (rs831571). Our predictive risk model presents new insights in DR development, which may assist in enabling timely intervention in reducing blindness in diabetic patients.


2010 ◽  
Vol 37 (12) ◽  
pp. 8102-8108 ◽  
Author(s):  
B.M. Patil ◽  
R.C. Joshi ◽  
Durga Toshniwal

Diabetes Care ◽  
2011 ◽  
Vol 34 (9) ◽  
pp. 2101-2107 ◽  
Author(s):  
Emmanuel Cosson ◽  
Minh Tuan Nguyen ◽  
Bernard Chanu ◽  
Isabela Banu ◽  
Sabrina Chiheb ◽  
...  

Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.


Sign in / Sign up

Export Citation Format

Share Document